Chemkart India Ltd reported revenue from operations of ₹99.60 crore for the period from April to June 2026 (Q1FY27). The company achieved nearly 50% of the previous financial year's full-year revenue in the first three months, alongside improved margins. This performance demonstrates rapid yet disciplined growth, providing strong momentum for the remainder of the financial year.

Ankit Mehta, Chairman & Managing Director, attributed the results to steady execution and the team's focus on building sustainable growth. He highlighted that the figures reflect a consistent build-up of sourcing capabilities, supplier relationships, and quality systems over time.

Strategic Developments

A key milestone during the period was achieved by the company's subsidiary, Vinstar Biotech Private Limited. It received trial orders from multiple customers for value-added ingredients developed in-house. This development validates the group's research and development capabilities and marks its transition from a supplier of ingredients to a developer of proprietary formulations.

The company is also investing in research and development to evolve into a complete solutions provider. This shift involves moving beyond product sales to offering customized solutions, including ingredient selection, application support, and formulation guidance. This transition is designed to deepen customer relationships and improve margin quality.

Manufacturing Expansion

Progress continued at the manufacturing facility under Easy Raw Materials Private Limited (EZRM). The project remains within its planned timeline, with civil work progressing as per schedule. Key milestones achieved during the period include the completion of plinth-level construction for Unit-1 and the receipt of the electricity sanction letter. Additionally, packaging machinery has been finalized, with delivery expected within 30-35 days of the purchase order release.

Operational Highlights

The company expanded its global supplier network and strengthened partnerships across key sourcing regions, with a specific focus on nutraceuticals. Chemkart also participated in three key industry exhibitions across India and Europe, including Vitafoods Europe in Barcelona, AAHAR in India, and Vitafoods India, to engage existing customers and build new relationships.

Promoter group member Jaini Shailesh Mehta has increased her shareholding in Chemkart India Ltd by acquiring 1,200 equity shares through an open market transaction on BSE Limited. The acquisition, executed on July 6, 2026, raised her total stake to 0.04% of the paid-up equity share capital. The disclosure was submitted to the exchange in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Prior to the transaction, Jaini Shailesh Mehta held 4,207 shares, accounting for a 0.03% stake. Following the purchase of 1,200 shares, her total holding stands at 5,407 shares. The company's total paid-up equity share capital is ₹12,09,90,000, divided into 1,20,99,000 equity shares of ₹10 each. The intimation regarding this acquisition was submitted to the company and the stock exchange on July 8, 2026.

Shareholding Details